Kostas Biliouris
Stock Analyst at Oppenheimer
(1.18)
# 3,755
Out of 5,182 analysts
66
Total ratings
37.04%
Success rate
-16.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $37 | $23.08 | +60.31% | 10 | Mar 19, 2026 | |
| PRME Prime Medicine | Initiates: Outperform | $11 | $3.41 | +222.58% | 2 | Mar 12, 2026 | |
| PEPG PepGen | Initiates: Outperform | $15 | $1.67 | +798.20% | 1 | Feb 25, 2026 | |
| KRRO Korro Bio | Upgrades: Outperform | $22 | $13.91 | +58.16% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $39.55 | +56.76% | 7 | Dec 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $319.52 | +47.10% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $73.89 | -5.26% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $0.67 | +498.98% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.48 | +129.89% | 2 | May 28, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $18.16 | +175.33% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $25 | $5.60 | +346.43% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $13.55 | +269.00% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.26 | +443.13% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.36 | +1,150.00% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $10.24 | +290.63% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $17.99 | +400.28% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $24.49 | +132.75% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $71.93 | -48.56% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $56.22 | +77.87% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $49.70 | +97.18% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Mar 19, 2026
Reiterates: Outperform
Price Target: $37
Current: $23.08
Upside: +60.31%
Prime Medicine
Mar 12, 2026
Initiates: Outperform
Price Target: $11
Current: $3.41
Upside: +222.58%
PepGen
Feb 25, 2026
Initiates: Outperform
Price Target: $15
Current: $1.67
Upside: +798.20%
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $13.91
Upside: +58.16%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $39.55
Upside: +56.76%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $319.52
Upside: +47.10%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $73.89
Upside: -5.26%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $0.67
Upside: +498.98%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.48
Upside: +129.89%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $18.16
Upside: +175.33%
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.60
Upside: +346.43%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $13.55
Upside: +269.00%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $6.26
Upside: +443.13%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.36
Upside: +1,150.00%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $10.24
Upside: +290.63%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $17.99
Upside: +400.28%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $24.49
Upside: +132.75%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $71.93
Upside: -48.56%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $56.22
Upside: +77.87%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $49.70
Upside: +97.18%